Vigilant Capital Management’s Edwards Lifesciences EW Stock Holding History

Vigilant Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-182	Closed	-$24K	–	591
2021 Q4	$24K	Sell	182 -440	-71%	-$51.3K	﹤0.01%	386
2021 Q3	$70K	Sell	622 -31	-5%	-$3.54K	0.01%	229
2021 Q2	$68K	Buy	+653	New	+$61.6K	0.01%	236
2018 Q4	–	Sell	-180	Closed	-$10K	–	458
2018 Q3	$10K	Hold	180	–	–	﹤0.01%	400
2018 Q2	$9K	Sell	180 -165	-48%	-$7.7K	﹤0.01%	418
2018 Q1	$16K	Buy	345 +165	+92%	+$7.17K	﹤0.01%	319
2017 Q4	$7K	Buy	+180	New	+$6.61K	﹤0.01%	355
2016 Q4	–	Sell	-384	Closed	-$15K	–	278
2016 Q3	$15K	Hold	384	–	–	﹤0.01%	245
2016 Q2	$13K	Buy	+384	New	+$13.1K	﹤0.01%	260

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vigilant Capital Management's EW Position: Q1 2022 in Review

Vigilant Capital Management sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 182 shares — an estimated $24K sold.

Vigilant Capital Management first reported a position in EW in Q2 2016 and held it in 9 quarters. The position peaked at $70K in Q3 2021. 1,314 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Vigilant Capital Management reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
Vigilant Capital Management sold 182 Edwards Lifesciences shares in Q1 2022, an estimated $24K.
Vigilant Capital Management first reported a position in Edwards Lifesciences in Q2 2016 and held it in 9 quarters.
Vigilant Capital Management's Edwards Lifesciences position peaked at $70K in Q3 2021.
1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Vigilant Capital Management's 13F filing for Q1 2022, filed 7 Apr 2022.